While melanoma‐derived EVs carrying PD‐L2 inhibited anti‐tumour activity and promoted tumour growth, tumours injected with PDL2 EVs exhibited a markedly improved response to anti‐PD‐1 treatment. The gene discussed is PDCD1LG2; the disease is melanoma.